Rob Bancroft Email & Phone Number

Orlando, Fl, Us

Nashville, Tennessee, Us

• Recruited by the President to develop and execute the launch strategy for DAXXIFY® in the therapeutics market, targeting a 2024 TAM of $3B.• Played a pivotal role in shaping the external Therapeutics narrative, including being one of five executives selected to present the company story to public markets on Investor Day.• Led development of a multi-phase launch plan, including a novel, real-world experience program with 30 KOLs that shaped the launch strategy and ensured key market access requirements (e.g., permanent J code, 80% coverage of total lives, comprehensive reimbursement services platform) were fully in place at launch.• Designed, hired, and built a launch organization of 35 professionals across sales, marketing, market access, sales ops, and medical affairs.• Achieved 27% month-over-month compounded growth during the immediate launch period (120% of plan in first full quarter) by optimizing KOL adoption and exceeding new account activation targets.

Boston, Ma, Us

• Provided executive leadership to navigate the COVID pandemic while driving key organizational, go-to-market, and fund raising initiatives for a SaaS startup fusing AI with neuroimaging to accelerate solutions for brain diseases.• Initiated a strategic assessment to quickly narrow product roadmap and sales channel priorities, thus focusing allocation of scarce resources, extending runway, and bringing clarity to fund raising efforts.• Attracted top-tier talent by recruiting the former Chief Marketing Officer for GE Global Healthcare as Chief Commercial Officer to lead a commercial leadership upgrade.• Raised $2M of post-seed funding to fuel continued company growth and extend financial runway towards Series A.

Jacksonville, Fl, Us

Retained by Chief Innovation Officer to scale Healogics Research Services, a new real world evidence venture based on their wound-specific, longitudinal outcomes database containing >3 million encounters. (1) Led data sciences in-sourcing strategy: managed relationship with 3rd party analytical supplier, retained industry-leading analytical expert, and recruited VP of Research & Analytics(2) Drove year one revenue of just under $1M by successfully initiating numerous industry relationships that led to multiple proposals, contracts, and repeat business for projects ranging from $35K - $250K(3) Delivered a broad range of analytical outputs including descriptive analyses, comparative effectiveness, patient journeys, machine learning models, single arm prospective study designs with synthetic control arms, etc.

• Led key business functions including sales, marketing, eCommerce, finance, and supply chain, to drive performance for a personally owned startup specializing in professional-grade skin and hair care products. • Partnered with CEO of the country’s largest network of PE-owned dermatology clinics to develop and manufacture an exclusive brand of skin and hair care products for their network of >150 clinics.• Increased sales of the proprietary, professional-grade skincare portfolio by over 20% through securing a distribution agreement with a Middle Eastern medical device company focused on aesthetics.

Watford, Hertfordshire, Gb

• Selected to design and lead the Strategic Development Group, a new team formed to drive the AWM global strategy.• Recruited key talent to deliver on critical capabilities: strategic planning, HEOR, new business development, business intelligence, and scientific communications – 39 employees total including 14 PhDs and 4 MDs.• Member of the AWM Global Executive Leadership Team overseeing ~$1.3 billion in global revenue.• Led Project 20/20, the 5 year strategic plan, to narrow focus to fewer and bigger bets: near term commercial focus on three product categories along with longer term shift from a product- to a disease-centric business model. • To support plan implementation, formed Strategy Council to govern organic and inorganic innovation investments – quickly led to acquisition of the Leaf Patient Monitoring System to support the ‘ownership’ strategy for pressure ulcers, the priority disease management target defined in Project 20/20.

• Led the newly acquired Biotherapeutics business, overseeing 600 employees, ~$300M in annual revenue, and managing a budget exceeding $200M as a member of the AWM Global Executive Leadership Team.• Spearheaded initiatives to exceed operating targets and enhance long-term growth, including a large sales force expansion and a shift in focus from site-of-service to physician-oriented call activity.• Led the successful re-launch of REGRANEX®, generating $25M (125% of plan) in revenue during the first full year by incorporating "beyond the molecule" service wrap-arounds to overcome prescribing barriers.• Blunted threat to SANTYL, a topical biologic driving the majority of growth, by leveraging a novel legal strategy based on the Lanham Act to secure an advantageous “Dear Customer” letter from a 510K competitor.• Drove the business to exceptional financial performance in 2013, achieving 47% growth (123% of plan), growing revenue from $190M to $280M, and generating $30M in operating profit (177% of plan).• Developed and implemented a reimbursement policy advocacy strategy to secure long-term product coverage, including joining BIO, initiating a PAC, engaging with Congress/Senate members, and educating CMS.

• Led enterprise strategy and multiple commercial departments (marketing, market access, HEOR, medical education) with a budget exceeding $12M, serving as a member of the Executive Leadership Team.• Delivered ‘Bioactive Leadership’ strategic plan that transformed the company from a broken business model with declining revenues to a wound sector star with 4 years of accelerating growth: +4% in 2009, +11% in 2010, +22% in 2011, and +28% in 2012.• Drove strategy execution by leading a corporate re-brand (from Healthpoint Limited to Healthpoint Biotherapeutics) championing the acquisition of REGRANEX®, and collaborating with R&D to establish scientific/evidence leadership.• Developed and presented the company’s investment thesis at multiple healthcare investment conferences and to multiple strategic buyers, financial investors, and Wall Street analysts.• Smith & Nephew acquired Healthpoint for $782M in 2012, surpassing ownership’s goal of monetizing for at least $500M by 2014.

Dublin, Coolock, Ie

Dublin, Coolock, Ie

Dublin, Coolock, Ie

Master Of Business Administration - Mba, Marketing, Finance

Bachelor Of Science (B.Sc.), Biology, General